Zanubrutinib

CAT#: H206830

CAS#: 1691249-45-2

Description: Zanubrutinib, aslo known as BGB-3111, is a potent and highly selective small molecule BTK inhibitor for the potential treatment of a variety of lymphomas. BGB-3111 selectively binds to and inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. Zanubrutinib has CAS#1691249-45-2 which is the S-isomer.

img

Synthetic Routes

Zanubrutinib - Synthetic Route 1

Zanubrutinib route01

Synthetic reference

Hilger, James; Zhang, Xiaoping; Feng, Shibao; Ro, Sunhee; Huang, Jane. Preparation of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide useful in combination with BTK inhibitors in treatment and prophylaxis of indolent or aggressive B-cell lymphomas. Assignee Beigene Switzerland GmbH, Switz. WO 2019108795. (2019).

Zanubrutinib - Synthetic Route 2

Zanubrutinib route02

Synthetic reference

Hu, Nan; Wang, Lai; Song, Jing; Zhang, Tong; Li, Kang; Luo, Lusong; Wei, Min; Wang, Zhiwei; Guo, Yunhang. Use of a combination comprising a Btk inhibitor and an immune checkpoint inhibitor for treating cancers. Assignee BeiGene, Ltd., Cayman I. WO 2018033135. (2018).

Zanubrutinib - Synthetic Route 3

Zanubrutinib route03

Synthetic reference

Guo, Yunhang; Wang, Zhiwei. Preparation of fused heterocyclic compounds as protein kinase inhibitors. Assignee BeiGene, Ltd., Cayman I. WO 2014173289. (2014).